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The role of CD4+FOXP3+ regulatory T cells (Treg) in human immunodeficiency virus (HIV)
infection has been an area of intensive investigation and remains a matter of ardent debate.
Investigation and interpretation suffered from uncertainties concerningTreg quantification.
Firstly,Treg quantification and function in HIV infection remain controversial in part because
of the lack of reliable and specific markers to identify humanTregs. Secondly, analyzingTreg
percentages or absolute numbers led to apparent discrepancies that are now solved: it is
now commonly accepted that Treg are targets of HIV infection, but are preferentially pre-
served compared to conventional CD4 T cells. Moreover, the duality of immune defects
associated to HIV infection, i.e., low grade chronic inflammation and defects in HIV-specific
responses also casts doubts on the potential impact ofTreg on HIV infection.Tregs may be
beneficial or/and detrimental to the control of HIV infection by suppressing chronic inflam-
mation or HIV-specific responses respectively. Indeed both effects of Treg suppression
have been described in HIV infection. The discovery in recent years of the existence of
phenotypically and functionally distinct human CD4+FOXP3+Treg subsets may provide a
unique opportunity to reconcile these contrasting results. It is tempting to speculate that
different Treg subsets exert these different suppressive effects. This review summarizes
available data concerning Treg fate during HIV infection when considering Treg globally or
as subsets. We discuss how the identification of naïve and effector Treg subsets modu-
lates our understanding ofTreg biology during HIV infection and the potential impact of HIV
infection on mechanisms governing peripheral differentiation of adaptive Tregs.
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INTRODUCTION
CD4+FOXP3+ regulatory T cells (Treg) are a critical CD4 T-cell
subset involved in the control of immune-tolerance by regulating
immune-homeostasis and limiting immune-activation. Defects in
Treg cell numbers or function have been related to the devel-
opment of human autoimmune diseases, while increases in Treg
numbers or activity could limit anti-tumoral immune-responses.
In contrast to these two scenarios, in which beneficial or detri-
mental roles of Treg are easily predictable, a much more complex
picture emerges for the role of Treg in infectious diseases. Treg
mediated inhibition of antimicrobial immune-responses could
lead to ineffective clearance of the pathogen contributing to the
chronicization of the infection. On the other side, Treg participate
to terminate immune-responses thus preventing exacerbated and
potentially harmful immune-activation (1, 2). The impact of Treg
during human immunodeficiency virus (HIV) infection is even
more difficult to integrate due to the dual features of HIV infection.
HIV infection is a chronic viral infection inducing drastic CD4
T-cell depletion that is associated with both immune deficiency
and dysregulated chronic immune-activation. The control of viral
replication is highly dependent on HIV-specific T-cell responses
as revealed by the analysis of patients who spontaneously control
the virus. Chronic inflammation sustains CD4+ T-cell decay and
participates to loss of functional CD8 T-cell activity. Improving
HIV-specific responses and limiting chronic immune inflamma-
tion are current goals of HIV therapies. Theoretically, Treg may
suppress both chronic immune inflammation and HIV-specific
responses being thus both beneficial and deleterious in HIV patho-
genesis (3, 4). Whereas the dual role of Treg in the pathogenesis
of HIV infection is now accepted, debates are still vivid to deter-
mine whether residual Treg exert these dual effects simultaneously
or sequentially. Interestingly, Treg inhibition does not solely apply
to immune functions, but also to the virus: Treg have also been
described to directly inhibit HIV infection and replication. Finally
additional complexity emerges from the observation that Treg may
constitute a potent reservoir, thus leading to consider infected
Tregs as an obstacle to efficient control of HIV infection. Deter-
mining the net impact of Treg cells on HIV infection remains a
matter of ardent debate and face major hurdles: (a) Treg quantifi-
cation during HIV infection remains controversial in part because
of the lack of reliable and specific markers to identify human Treg;
(b) expression of Treg quantification using percentages or absolute
numbers led to obvious discrepancies that need to be discussed;
(c) HIV infection recovers multiple immunological and viral status
including patients during primary infection, chronically viremic
patients, aviremic antiretroviral therapy (ART) treated patients
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or spontaneous controllers, which should be considered indepen-
dently; (d) the accuracy of Treg analysis in the blood versus crucial
sites such as lymph-node or gut associated mucosa is also under
debate; (e) Treg have been essentially identified so far as a unique
population whereas increasing evidence demonstrate high diver-
sity in function and ontogeny. One may also question whether
different Treg subsets may differently modulate HIV pathogene-
sis. Integrating Treg heterogeneity may prove crucial to dissect the
impact of Treg mediated suppression during HIV infection. In the
present review we will focus on Treg phenotypic and functional
heterogeneity in order to elucidate Treg fate during HIV infection
and to better delineate the protective or pathogenic roles of Treg
cells in HIV infection.
HIV INFECTION AND GLOBAL TREGS
IDENTIFICATION STRATEGIES
Firstly identified in 1995 in mice as a suppressive CD4 T-cell sub-
set constitutively expressing the IL-2 receptor alpha-chain (CD25)
molecule (5), Treg have been subsequently identified in humans
as a CD4 T-cell subset exhibiting in vitro suppressive proper-
ties and expressing high levels of CD25 (6–10). Unfortunately,
the inducible nature of CD25 expression during T-cell activation
on conventional T cells renders this molecule unsuited for Treg
identification during immune-activation. Shortly thereafter, the
forkhead box P3 (FOXP3) transcription factor was identified as
an essential and specific factor for Treg development and func-
tion (11–13). While FOXP3 is to date the most specific marker
for Treg identification in mice, in humans the situation is more
complex, as the expression of FoxP3 is also observed in some con-
ventional CD4+CD25−T cells upon activation (14). Finally, it has
been shown that human CD4+FOXP3+CD25high cells express
lower levels of CD127, the alpha-chain of the IL-7 receptor, when
compared with their FOXP3-counterpart (15–17). The combina-
tion of the CD25 and CD127 surface markers with or without
intra-nuclear staining for FOXP3 expression has thereafter been
widely employed to identify CD4+ Treg cells (Figures 1A–C).
Sorting of Treg cells has greatly benefited from the combina-
tion of high CD25 and low CD127 expression. However such an
approach also presents drawbacks: conventional non-Treg CD4
T cells down-regulate CD127 expression during activation while
they up-regulate CD25. It is therefore likely that CD127 and CD25
expression cannot accurately discriminate ex vivo Treg cells from
activated T cells in situations of immune-activation such as HIV
infection (18). In conclusion, Treg identification in context of
chronic activation such as HIV infection, still suffers from the
lack of indisputable markers that can unequivocally distinguish
Treg from effector cells.
TREG SUSCEPTIBILITY TO HIV INFECTION AND SUPPRESSIVE
PROPERTIES
Several studies have shown in vitro that Treg cells are highly sus-
ceptible to HIV infection (19–22). Moreover, Treg susceptibility
seems to differ depending on the HIV type 1 strain, Treg being
less susceptible to R5 viruses compared with effector T cells (22).
Interestingly, Tran et al. suggested that Treg could represent a pref-
erential cellular reservoir of viral infection (21). Treg suppressive
capacity does not seem to be affected by HIV infection as Treg
isolated from acutely (23), chronically viremic (24, 49) infected
patients, or HIV controllers (24, 49) suppress effector T cells
proliferation as efficiently as Treg isolated from healthy donors.
TREG QUANTIFICATION IN HIV INFECTION
Regulatory T cells quantification in HIV infection remains contro-
versial in part because of the aforementioned lack of homogeneous
and reliable specific markers to identify human Tregs. A second
hurdle arises from the strategy used to quantify Tregs. Because
CD4 depletion is the pathogenic hallmark of HIV infection and
CD4 counts decline during disease progression, determining Treg
percentages among CD4 T cells or Treg counts does not pro-
vide similar information and thus participates to the uncertainties
concerning Treg quantification. Both quantifications have their
advantages and drawbacks. Percentages allow analyzing relative
proportion of Tregs among CD4 T cells regardless the intensity of
CD4 T-cell depletion associated to HIV infection. Conversely, Treg
numbers allow evaluating potential bias in effector non-CD4 T-
cell/Treg ratio since Treg suppression not only affects CD4 T cells
but also effector CD8 T cells and innate cells. Interestingly, these
two analyses led to different observations: Treg numbers are essen-
tially reduced during HIV infection, but Treg are preferentially
preserved compared to conventional CD4 T cells thus diversely
impacting Treg percentages among CD4 T cells. Extreme care
should be taken when interpreting these opposing data. Increasing
Treg percentages among CD4 T cells suggest increasing Treg medi-
ated suppression capacities against CD4 T cells, but reduced Treg
numbers suggest reduced suppression capacity on other cellular
targets (CD8 T cells, NK cells, dendritic cells). It thus seems rele-
vant to provide both sets of information to finely dissect the global
impact of Treg during HIV infection. Such particular feature of
Treg alteration during HIV infection may provide an important
rationale to understand diversity of Treg mediated effects. Finally,
a third major aspect participating to the discrepancies obtained
is represented by the diversity of HIV clinical stages rendering
universal conclusion difficult to be drawn. Exhaustive analyses
addressing the different immunological and virological status of
HIV patients finally allowed some consensual conclusions to be
formulated. During primary HIV infection (PHI), decreased Treg
percentages (23, 25, 26) and absolute numbers (26) have been
described, although results differ depending on the staining strat-
egy (25). In chronically infected viremic patients, Treg percentages
are shown to be consistently increased while Treg absolute num-
bers consistently decreased (24, 26–35). During efficacious ART
Treg percentages have been shown to progressively decrease to
normal levels (33, 36–40) while Treg counts increase progressively
in parallel with total CD4 counts (24, 33, 37–39, 41). Interestingly
this effect is reversed upon ART interruption (42). Studies of Treg
levels in HIV controllers, a subpopulation of patients who spon-
taneously control viral loads (43), revealed alternately unchanged
(20, 24, 39, 44), increased (45), or reduced (26, 46) percentages
compared to healthy donors. Treg absolute numbers have been
reported to be either unchanged (39) or decreased (26) in HIV
controllers compared to healthy individuals. Importantly, analy-
ses of Treg homeostasis were also performed apart from peripheral
blood and notably in gastrointestinal mucosa which represents a
major site of viral replication and CD4 T-cell depletion, and thus
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FIGURE 1 | Flow cytometryidentification strategies ofTreg subsets.
(A) Global Treg identification based on FOXP3, CD25, and CD127
expression by CD4 T cells. (B) Expression of CD45RA and FOXP3 by CD4 T
cells allows the identification of CD45RA+ FOXP3low resting or naïve Treg
and CD45RA- FOXP3high activated or effector Treg. (C) Treg proportions
and absolute numbers obtained employing different existing gating
strategies. (D) Further identification of effector Treg subsets based on
HLA-DR or Ki67 expression. HLA-DR or Ki67 expression in global CD4 T
cells (gray), CD45RA+ FOXP3low naïve Treg (green), or CD45RA-
FOXP3high effector Treg (red) is shown.
represents a central site involved in HIV infection pathogenesis.
Few studies investigating Treg levels in the intestinal tract demon-
strated that during viremic HIV infection a global CD4 T-cell loss
takes place in gastrointestinal mucosa with preferential preser-
vation of Treg, leading to a relative increase in Treg proportion
(24, 47–49). Such a process is reversed by efficient ART dur-
ing which restoration of normal Treg levels in gastrointestinal
tract is observed (24, 47–49). Collectively, data obtained from
intestinal tract thus corroborated data obtained from peripheral
blood showing a reduction of Treg numbers in peripheral blood
and gut mucosa during viremic stages, although Tregs appeared
preferentially preserved among CD4 T cells at both sites.
IMPACT ON HIV PROGRESSION
Several studies tried to evaluate in vivo Treg role on HIV infec-
tion by correlating Treg percentages or numbers to different
canonical parameters of HIV disease, i.e., CD4 count, viral load,
and activation profile. Most of published studies agree in report-
ing a positive correlation between absolute numbers of Treg and
CD4 counts (26, 28, 31, 37, 39, 50–54) and a negative correla-
tion between Treg percentages and CD4 counts (27, 29, 31, 34, 37,
39, 55, 56). One may discuss the relevance of correlation between
CD4 counts and Treg counts because Treg are a CD4 T-cell sub-
set. Interpretations were thus mostly drawn from correlation with
viral load and/or activation profile. Viral load has been reported
mostly to be positively correlated to Treg percentages (29, 39,
40, 55, 57) and negatively correlated with Treg numbers (31, 39,
51, 58). These observations led to investigate a direct impact of
Treg on HIV-specific CD4 and CD8 T-cell responses. It has been
shown that presence of CD4+ CD25+ cells during in vitro HIV-
specific stimulation led to decreased HIV-specific CD4 and CD8
responses (20, 21, 23, 50, 51, 59–66). Importantly, Treg have been
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reported to suppress both cell proliferation and effector mole-
cules production in response to HIV. Recently, Elahi and coworkers
reported the interesting finding that Treg cells differentially sup-
press HIV epitope proliferation of CD8+ CTLs depending on
HLA alleles restriction, epitope-specific CD8+ CTLs restricted
to the protective HLA allele groups HLA-B∗27 and HLA-B∗57
being not susceptible to Treg mediated suppression (63). Col-
lectively, published results suggest that a dominant mechanism
of suppression by Treg could reduce in vivo antiviral responses
participating to the incapacity to eradicate HIV infection. How-
ever, ex vivo correlation studies failed to detect any association
between global Treg levels and HIV-specific T-cell responses in
terms of IFN gamma (IFN-γ) production in response to HIV
peptides stimulation (24, 40, 44, 51) or HIV-specific CD8 T-cell
activation (26).
Immune hyper-activation as revealed by expression of CD38
and HLA-DR activation markers at CD4 and CD8 cell surface
is a negative prognostic factor associated with disease progres-
sion in HIV infection (67, 68). In order to investigate if Treg
alteration played a role in this phenomenon, several studies have
tried to identify a correlation between Treg level and lympho-
cytes activation. Unfortunately no clear conclusion can be drawn
using expression of CD38 and HLA-DR expression analyses to
evaluate CD4 and CD8 activation. Conflicting results have been
reported concerning relationship of Treg with immune-activation
in PHI depending on Treg identification strategy employed (23,
69). Similarly, no consensus has been reached in studies includ-
ing patients during chronic viremic infection when either positive
(29, 53), negative (25, 51, 70), or no correlations (32, 55) between
Treg levels and immune-activation have been reported. The only
stage of infection in which some conclusion can eventually be
reached is represented by aviremic patients undergoing ART in
which several studies concluded for an inverse correlation between
Treg proportions and T-cell activation (36, 42). Based on these
observations some authors speculated that Treg could be suf-
ficient to control low residual T-cell activation in ART-treated
patients, but insufficient to affect generalized immune-activation
observed during primary or chronic viremic HIV infection (4). In
this hypothesis, restoring Treg pool in ART-treated patients may
thus constitute an interesting strategy ensuring Treg suppression
without affecting viral load control. IL-2 recombinant injection
induces significant increase in Treg numbers (111) although no
clinical benefits were observed from restoration of Treg pools, cast-
ing doubts on the relevance of Treg compartment on the control
of immune-activation (71). However, the Treg subsets preferen-
tially increased upon IL-2 treatment are not fully characterized.
It could be useful to consider manipulation of specific Treg sub-
sets to provide beneficial impact. Collectively, these contrasting
results reinforce the notion that Treg could be a double edged
sword during HIV infection. On one side, they are detrimental
as they inhibit HIV-specific immune response. On the other side,
they could participate to the maintenance of immune-homeostasis
by reducing non-specific chronic immune hyper-activation. Tak-
ing into account Treg heterogeneity may prove crucial to dissect
these opposite effects of Treg mediated suppression during HIV
infection.
HIV INFECTION AND TREGS SUBSETS
Similarly to other T-cells compartments, Treg population presents
a high degree of heterogeneity both in humans and mice. Several
markers allow the identification of phenotypically distinct Treg
subsets, and controversies exist about which Treg subpopulations
present peculiar functional characteristics. As described for con-
ventional T cells, distinction between naïve and effector cells have
been considered for Treg subsets. CD45RA or CD45RO expres-
sion has been notably considered to identify naïve and effector
Tregs. Such strategy offers interesting insight on the biology of
Tregs in HIV infection as discussed below, being an initial step
that partially reflects the heterogeneity among Treg subsets. Other
markers, such as HLA-DR or Inducible costimulatory molecule
(ICOS), have been reported to identify cells at other stages of
activation and, more importantly, seem to identify peculiar Treg
cell subsets provided with specific mechanisms and effects of sup-
pression. Finally, some molecules implicated in Treg suppressive
function, such as CD39 and Glycoprotein A repetitions predom-
inant (GARP), are employed to identify peculiar Treg subsets.
Defining additional markers and/or combination will undoubt-
edly allow further refining of Treg subsets preservation during the
course of HIV infection. Identification of Treg subsets using acti-
vation markers and their respective impact on HIV infection will
be briefly presented when information is available.
SUBDIVISION IN NAÏVE AND EFFECTOR TREG SUBSETS
Several studies have shown that CD45RA is an extremely use-
ful marker for Treg identification when combined to CD25 (72,
73, 110) or FOXP3 (74). CD45RA expression allows the reparti-
tion of the FOXP3+ CD4 T-cell population in three subsets: (i)
FOXP3low CD25low CD45RA+ cells, (ii) FOXP3high CD25high
CD45RA− cells, and (iii) a FOXP3low CD25low CD45RA− pop-
ulation (74) (Figures 1B,C). FOXP3low CD25low CD45RA+
cells represents in human peripheral blood approximately 2–
4% of CD4 T cells and 20–30% of “global” CD4+ FOXP3+
CD25high CD127low T cells. Accordingly to their “naïve” pheno-
type, CD45RA+ FOXP3low CD25low Tregs constitute the great
majority of CD25 or FOXP3 expressing CD4 T cells in cord
blood (73, 74). In classical in vitro suppressive assays CD45RA+
FOXP3low naïve Treg cells efficiently suppress effector T-cell pro-
liferation (74). Interestingly during activation these cells actively
proliferate, are highly resistant to apoptosis and convert to a
CD45RA-CD45RO+ phenotype (74). It is important to note that
early studies of human Treg based on the CD25high gating strategy
initially proposed by Bacher-Allen (6, 75) inadvertently excluded
the CD25low naïve Treg population from the analysis.
CD45RA− FOXP3+ CD4+ T cells include as mentioned two
phenotypically and functionally distinct cellular subpopulations:
(i) a FOXP3low CD25low CD45RA− cytokine-secreting cell pop-
ulation which lacks suppressor activity (ii) a suppressive effector
FOXP3high CD25high CD45RA− Treg population (74). Such an
analysis presents the major advantage of allowing the exclusion
of the FOXP3+ non-Treg contaminating cells, which are included
when the classical FOXP3+ CD25hi CD127low gating strategy is
employed. FOXP3high CD25high CD45RA− effector Treg effi-
ciently suppress conventional effector T-cell responses in vitro
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but, in contrast to CD45RA+ naïve Treg, are highly suscepti-
ble to apoptosis and mostly die while exerting their suppressive
function (74). CD45RA+ naïve Treg are able to differentiate into
FOXP3high CD25high CD45RA− effector Treg upon in vitro
and in vivo activation (74). However, whether the FOXP3high
CD25high CD45RA− effector Treg pool is entirely represented by
activated thymic derived Treg or can be composed by peripherally
differentiated induced Treg (iTreg) still remains unknown.
CD45RA+FOXP3low naïve Treg cells
CD45RA+ FOXP3low CD25low Treg counts have been reported
to be significantly reduced in HIV-infected patients when com-
pared with healthy donors (26, 76). When different HIV diseases
stages are taken into account naïve Treg counts reduction seems
to be exclusively restricted to the PHI phase, while no differ-
ence is observed when viremic and aviremic chronically infected
patients are considered (26). The majority of naïve CD45RA+
FOXP3low CD25low Treg also express CD31 (platelet endothelial
cell adhesion molecule-1, PECAM-1), a cell surface marker iden-
tifying recent thymic emigrants. Proportions of CD31+ among
naïve Treg are not affected during acute or chronic HIV infection
indicating preserved Treg thymic differentiation (77). Naïve Treg
express high levels of the HIV co-receptor CXCR4 while CCR5 is
barely detectable at their surface (76–78). In vitro experiments have
demonstrated that CD45RA+ naïve Treg are more susceptible to
HIV infection when compared to conventional CD45RA+ naïve
CD4 T cells (76, 78). Accordingly to their phenotype naïve Treg
were more susceptible to in vitro infection when CXCR4-tropic
strain (HIV-1 IIIB) was used rather than CCR5-tropic strain using
HIV-1 BaL (76).
Regarding the association of naïve Treg cell numbers and
parameters of disease in HIV infection, naïve Treg cell numbers
positively correlate with CD4 count in both healthy donors and
HIV-infected patients (26, 31, 76) independently from the stage of
the disease. No association (76) or only weak inverse correlation
(26, 31) between levels of HIV RNA levels and number of naïve
Tregs have been reported. Finally, naïve Treg cell numbers correlate
neither with global CD8 T-cell activation nor with HIV-specific
CD8 T-cell responses (26).
Globally, current evidence indicates that naïve Treg subset
is minimally affected during HIV infection being altered exclu-
sively during early phases of infection (primary infected patients).
Ex vivo correlation analyses indicate only marginal role of naïve
Treg on HIV infection.
CD45RO+ FOXP3high CD25high effector Treg cells
No differences (26, 76) or increase (77) were reported in propor-
tions of effector Treg among CD4 T cells during viremic chronic
infection. In contrast, viremic chronically HIV-infected patients
present a significant reduction in effector Treg cell counts when
compared with healthy donors (26, 76), and this phenomenon
was observed in other settings of disease including patients dur-
ing PHI, aviremic patients under antiretroviral treatment, and
HIV controllers (26). Therefore, effector Treg depletion appears
to take place early during HIV infection and to persist during
chronic phases of infection, while ART seems not to be able to
restore the effector Treg pool. However, further studies analyzing
cohorts followed up longitudinally may be needed to determine
the effects of ART on reconstitution of the effector Treg subset.
Accordingly to its expression on recent thymic emigrants, CD31 is
barely detectable at effector Treg surface (74). Interestingly, Zhou
and coworkers showed increased proportions of CD31 express-
ing effector Treg in both acutely and chronically HIV-infected
patients suggesting higher conversion from a naïve to an effector
Treg phenotype during HIV infection (77).
Phenotypic analysis of effector Treg revealed high levels of
expression of the HIV co-receptor CCR5 while CXCR4 is expressed
at lower levels at effector Treg surface when compared to naïve
Treg cells (76, 77). Such a differential pattern of HIV co-receptor
expression between naïve and effector Treg cells suggests potential
differences in viral strains infection susceptibility. Indeed, effec-
tor Treg were more susceptible than naïve Treg to in vitro HIV
infection by CCR5-tropic HIV-1 BaL while naïve and effector Treg
were similarly susceptible to CXCR4-tropic HIV-1 IIIB in vitro
infection (76).
Some conclusions can be drawn from correlation analyses
regarding the role played by effector Treg in HIV infection. Effec-
tor Treg numbers positively correlate with CD4 counts in healthy
donors and such a correlation is lost in chronically HIV-infected
individuals (26, 76) presumably reflecting a preferential loss of
the effector Treg subset. Lack of correlation between effector Treg
numbers and CD4 counts was similarly found in patients during
PHI and in individuals under efficacious ART (26), suggesting an
early impairment in effector Treg homeostasis during HIV infec-
tion which is not restored by ART. Interestingly, the correlation was
observed in HIV controllers, indicating a preserved effector Treg
pool in this peculiar patient population. No correlation between
effector Treg counts and HIV viral load (26, 76) or global CD8 T-
cell activation (26) has been reported. Aiming to determine the role
of effector Treg in modulation of HIV-specific immune-responses,
we found an inverse correlation between effector Treg counts and
both HIV-specific CD8 activation and interferon gamma produc-
tion by CD8 upon stimulation by HIV peptides (26). These ex
vivo results suggest a dominant suppression exerted by Treg on
HIV-specific CD8 T-cell responses potentially participating to the
incapacity to control the virus. Globally, available data indicate
a preferential, precocious, and long-lasting effect of HIV infec-
tion on the effector Treg compartment. Analyses of association
between Treg subsets and HIV disease parameters, while failing
to detect any potential link with the naïve Treg subset, point
to a deleterious effect of effector Treg in HIV infection patho-
genesis. Further studies will eventually confirm the dominant
suppressive role exerted by effector Treg on HIV-specific immune-
responses currently suggested by observational data. Surprisingly,
no or low correlation was detected between Treg and immune-
activation so far. One may discuss the accuracy of the immune
markers selected to determine such association. Secondly, speci-
ficity of effector Treg cells recovered during HIV infection also
introduces heterogeneity. Demonstrating whether residual effec-
tor Treg are specifically targeting HIV related epitopes may fur-
ther ascertain or infirm the specific role of Treg on HIV-specific
responses.
ADDITIONAL SUBDIVISION AMONG EFFECTOR TREGS
Although highly altered in numbers by HIV infection, effec-
tor Tregs recovered from HIV-infected patients exhibited various
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phenotypic profiles. The relative susceptibility to HIV infection of
each effector Treg subsets and their respective suppressive capacity
remains to be further elucidated.
HLA-DR
MHC-II expression identifies a population that represents about
20–30% of human circulating Treg cells (6, 79). Ex vivo iso-
lated HLA-DR+ Treg cells suppress responder T-cell prolifera-
tion and cytokine secretion more efficiently and more rapidly
than HLA-DR-Treg cells (79). Importantly, all HLA-DR+ Treg
cells are part of the effector FOXP3highCD45RA− compartment
(74) (Figure 1D) of which they seem to constitute a terminally
differentiated subset [reviewed in (80)].
Little is known about the effects of HIV infection on HLA-DR+
terminally effector Tregs or about the role exerted by this subset in
the pathophysiology of the disease. Higher proportions of HLA-
DR expressing Treg are present in chronically viremic HIV-infected
patients when compared to healthy donors (81, 82) and Treg from
patients presenting higher viral loads express higher levels of HLA-
DR (81). ART fails to normalize HLA-DR+Treg proportions (82).
Unfortunately, no information about HLA-DR+ terminally effec-
tor Treg counts is available and further studies may be needed to
determine whether the reported alterations merely reflect a pheno-
typic modification linked to the activation status or whether HIV
infection directly alters HLA-DR+ terminally effector Treg home-
ostasis. Correlation analysis demonstrated an inverse correlation
between proportions of HLA-DR+Tregs and CD4 counts (81, 83),
while a positive correlation was reported between percentages of
HLA-DR positive cells among Treg and viral load (83) or CD4 and
CD8 T-cell activation as revealed by HLA-DR or CD38 expression
(81). Once more it is currently impossible to ascertain whether
these relationships simply reflect HLA-DR up-regulation at Treg
surface as a result of the global immune-activation observed dur-
ing HIV or identify terminal effectors HLA-DR+ Treg as players
in HIV physiopathology.
Ki67
Intracellular Ki67 staining identifies an actively proliferating frac-
tion of Treg cells. In both mice and humans the percentage of Ki67
cells among FOXP3+ cells is higher than the percentage among
conventional FOXP3−CD4 T cells (84). This is in accordance with
their more activated profile. Notably, all cycling Ki67+ Treg cells
are part of the effector FOXP3highCD45RA− compartment (74)
(Figure 1D). During HIV infection, higher proportions of Ki67+
Treg are present during acute (77) and chronic viremic (33, 77,
83, 85) phases of infection. Longitudinal studies indicate that ART
leads to normalization of Ki67+ Treg percentages (77, 83). Long
term non-progressors present similar proportions of Ki67+ Treg
as healthy donors (83) while no data are available in HIV con-
trollers. Higher proportions of Ki67+ Treg seem to be associated
with disease progression during chronic HIV infection as percent-
ages of Ki67+ Treg correlate negatively with CD4 counts (33, 83)
and positively with viral loads (33, 83). Collectively, higher levels
of Ki67+ Treg have been associated with more advanced disease
although studies addressing Ki67+ Treg counts and eventually
analyzing HIV controllers could provide further insights into the
role of this Treg subset in HIV physiopathology.
OTHER SUBSETS
CD39
CD39, also referred to as ENTPD-1, is a member of the
ectonucleotidase triphosphate diphosphohydrolase family which
hydrolyzes extracellular ATP and adenosine diphosphate (ADP)
into adenosine monophosphate (AMP). Through CD39, Tregs
can generate the inhibitory molecule adenosine which suppresses
effector T cells by binding to the adenosine receptor 2A at their
surface (86). While murine Treg mice globally express CD39 at
their surface (86, 87), CD39 expression in human Treg is restricted
to a subset of CD45RO expressing cells mostly co-expressing HLA-
DR (87). Proportions of CD39+ Treg are significantly increased
in HIV-infected patients, included chronic viremic patients, anti-
retroviral treated individuals, and long term non-progressors (39,
65, 82). Interestingly, HIV controllers present proportions of
CD39+ Treg similar to healthy donors (39). Longitudinal analysis
confirmed that antiretroviral treatment fails to normalize propor-
tions of CD39+ Treg (39). In vitro suppression assays revealed
that the suppressive effect of Treg on cytokines production of
Gag-stimulated CD8+ T cells is partially reversed by the addi-
tion of CD39 blocking mAb (65), pointing to a role for CD39 in
Treg suppression of HIV-specific responses. Interestingly, CD39 is
also involved in Treg control of HIV viral replication (64). CD39
expression on Treg correlates negatively with CD4+ T-cell count
and positively with viral load and T-cell activation in HIV-1 posi-
tive subjects (39, 65). Globally, current evidence points to a major
role for CD39 expression on Treg, participating to Treg mediated
suppression of HIV-specific responses and disease progression.
Inducible costimulatory molecule
Inducible costimulatory molecule is a costimulatory molecule
involved in cell activation that is expressed on effector/memory
T-cell subsets. In mice, ICOS represents an activation marker
at the Treg surface. Ex vivo, its expression identifies a sizable
population which represent about 10–20% of CD4+FOXP3+ T
cells isolated from secondary lymphoid organs. Whether ICOS
expression exerts any function in Treg activity is still unknown.
In humans differential expression of ICOS has been shown to
delineate two different subsets of Treg cells in the peripheral
blood (88). Interestingly, these two phenotypically distinct subsets
present differences in their suppressive capacity and in the mech-
anisms of action employed: ICOS− Treg suppression is mainly
mediated by TGF-β while ICOS+ Treg suppression relies pre-
dominantly on IL-10 (88). Higher proportions of ICOS express-
ing Treg have been reported in several populations HIV-infected
patients, including viremic chronically infected patients, antiretro-
viral treated individuals, and HIV controllers (39). Longitudinal
analysis revealed significant decrease of ICOS expressing Treg
following ART treatment (39).
Glycoprotein A repetitions predominant
Glycoprotein A repetitions predominant (or LRRC32) is a trans-
membrane protein selectively expressed by activated Treg but not
conventional CD4 T cells (89–91). Ex vivo, GARP identifies a
subset of activated FOXP3+ T cells with high suppressive capac-
ity. While barely expressed on CD45RA+ naïve Treg, GARP is
promptly up-regulated upon in vitro TCR-stimulation on both
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naïve and total Treg cells, while no expression is detected on acti-
vated conventional T cells (90). Moreover, human CD4 T cells in
which FOXP3 expression was induced by activation in the pres-
ence of TGF-β failed to express GARP, leading to the hypothesis
that GARP could be employed to identify bona fide Tregs (90). Two
studies comparing GARP+ Treg proportions in healthy donors
and HIV-infected individuals, failed to detect any significant dif-
ference (82, 90). This result was in discordance with the increase in
proportions of FOXP3+ CD4 T cells reported in the same studies,
leading to the hypothesis that a portion of FOXP3+T cells detected
during HIV infection are possibly recently activated cells and/or
iTreg. Further studies combining GARP expression with effector
Treg and iTreg identification strategies will eventually clarify this
issue.
SUBDIVISION IN EXTRATHYMICALLY INDUCED OR ADAPTIVE TREGS
In addition to their activation profile, Treg has also been dissected
in two subsets: natural Tregs originating from the thymus and
extrathymically iTregs or adaptive Tregs generated in the periphery
under a variety of conditions through conversion from naïve con-
ventional CD4+ cells. Several mechanisms have been implicated
in induced Foxp3+ Treg (iTreg) peripheral generation, includ-
ing cytokines (TGF-β, IL-2) and metabolic pathways (tryptophan
metabolism, retinoic acid).
EX VIVO iTREG IDENTIFICATION
Ex vivo quantification of iTreg during HIV is limited by the
unavailability of a specific marker for identification of bona fide
iTreg. Several markers have been proposed for iTreg identifica-
tion but their specificity in distinguishing natural thymic derived
Treg from peripherally differentiated iTreg is still a matter of
debate.
Helios
The transcription factor Helios, a member of the Ikaros transcrip-
tion factor family, has been reported to be expressed by 100%
of CD4+CD8−Foxp3+ thymocytes and about 70% peripheral
Foxp3+ T cells in mice and humans (92). Interestingly, murine
or human naïve T cells acquiring Foxp3 expression upon in vitro
TCR-stimulation in the presence of TGF-β failed to express Helios,
suggesting that absence of Helios expression could be employed
to identify peripherally differentiated iTreg (92). However, sub-
sequent reports showed that depending on the stimulation con-
ditions, Helios could be induced in parallel with Foxp3 in iTreg
(93–95). Moreover, Helios was reported to represent a T cell acti-
vation and proliferation marker thus being independent from Treg
lineage commitment (96). Finally, natural Treg recent thymic emi-
grants have been shown to contain a fraction of Helios negative
cells (97). Regardless its limited reliability as a maker differentiat-
ing nTreg from iTreg, Helios expression allows the identification
of a subset of Treg cells presenting some peculiar characteristics.
Murine Helios+ Treg express higher levels of CD103 and GITR
at their surface and produce higher levels of TGF-β (94). Inter-
estingly, murine and human data indicate that Helios+ Treg are
relatively over-represented in tumors, pointing to this cell sub-
set as a potential target for immune-modulating strategies (94,
98, 99). Currently, no information is available concerning Helios
expression on Treg cells during HIV infection. Further studies
will eventually define whether HIV infection differentially affects
Helios+ and Helios− Treg subsets homeostasis and whether these
subsets play a distinct role on HIV pathophysiology.
Neuropilin-1
Neuropilin-1 (NRP1) is a semaphorin III receptor participating
in axon guidance, angiogenesis, and involved in the immuno-
logical synapse, which has been recently reported in mice to be
expressed at high levels on thymic derived nTreg cells but not
on peripherally generated iTreg (100, 101). Importantly, NRP1
expression remains stable on NRP1 positive or negative Treg
subsets upon TCR mediated or lymphopenia induced cell activa-
tion and proliferation while environmental inflammatory stimuli
have been shown to modulate NRP1 expression (101). Therefore,
NRP1 expression has been suggested as a potential marker dis-
tinguishing nTreg from iTreg, at least in steady state conditions.
Whether these results obtained in the murine system can be trans-
lated to human cells still remains to be addressed. In humans,
NRP1 seems to be expressed exclusively by a subsets of lymph-
node resident Treg subset (102) while Treg isolated from human
peripheral blood fail to express significant levels of NRP1 (102,
103). One study performed in HIV infection assessed propor-
tions of Neuropilin-1 expressing CD4 T cells and correlation with
other Treg markers and failed to detect any significant difference
between healthy donors and viremic or aviremic antiretroviral
treated HIV+ patients (104).
HIV INFECTION FAVORS PERIPHERAL TREG INDUCTION
Numerous studies suggest an effect of HIV on iTreg cells genera-
tion mainly through modulation of antigen presenting cells (APC)
tolerogenicity. Plasmacytoid dendritic cells (pDCs) represent a
crucial subset of APC involved in antiviral immunity and a major
target of HIV infection. Through Toll-like receptor 7 stimulation,
HIV modulates pDC activation by simultaneously inducing type I
IFN production and up-regulation of indoleamine 2,3 dioxygenase
(IDO) expression (105, 106). IDO is an enzyme involved in tryp-
tophan catabolisms which exerts immuno-modulatory functions
by inhibiting T-cell proliferation and inducing iTreg peripheral
generation. HIV-activated human pDC induce the peripheral
generation of iTreg (106) through IDO up-regulation. Conse-
quently, iTreg induced by HIV-activated pDC modulate myeloid
dendritic cells (mDC) maturation and function partially through
cytotoxic T-lymphocyte antigen (CTLA)-4 engagement, inhibiting
their maturation and inducing IDO expression (106, 107). CTLA-
4-conditioned mDC can in turn induce Treg differentiation in
an IDO-dependent manner (107). Whether HIV could directly
modulate mDC capacity to generate iTreg still remains unclear.
Lymph-node resident mDC from viremic but not ART-treated
HIV-infected subjects induce iTreg differentiation phenotype of
normal allogeneic T cells (108). Accordingly, preclinical data in
the SIV infection model indicate that mature splenic or mesenteric
mDCs from SIV-infected animals are significantly more efficient at
inducing Treg than mDCs from uninfected animals (82). However,
experimental evidence indicates that in vitro infection of mDC
with CCR5-utilizing virus or even simple exposure of mDC to
inactivated HIV significantly impairs their ability to induce iTreg
differentiation (109).
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FIGURE 2 | Schematic representation ofTreg subsets during HIV
infection. CD4 T cells originate in the thymus as Natural FOXP3+Treg or
conventional FOXP3−T cell. Once in the periphery, natural CD45RA+
FOXP3low naïve Treg cells further differentiate into effector CD45RA-FOXP3hi
and terminal effector CD45RA-FOXP3hiHLADR+Tregs (left panel ). On the
other side, upon activation under specific tolerogenic conditions such as
tolerogenic antigen presenting cells (APC) expressing indoleamine 2,3
dioxygenase (IDO), conventional naïve FOXP3− CD4 T cells can convert
extrathymically into induced FOXP3+Treg (iTreg) (right panel ). Phenotypic
markers expressed during Treg subsets differentiation or peripheral iTreg
conversion are indicated. Essential aspects of Treg subsets relationship with
HIV infection are summarized.
CONCLUDING REMARKS
Human Treg quantification, especially in contexts of chronic
immune-activation such as HIV infection, still remains uncer-
tain essentially because of limitations in identification strategies.
We discussed how dissecting Treg heterogeneity provided addi-
tional insights on the biology of Treg during HIV infection. A
schematic representation of Treg subsets during HIV infection is
provided in Figure 2. Currently two main strategies are used to
classify and characterize Treg subsets. In accordance with clas-
sification established for conventional T cell, analyses of “naïve”
and effector Tregs have been considered. Importantly, naïve and
effector Treg discrimination led to better identification of Treg by
limiting contamination by Foxp3low non-Treg cells. Use of clas-
sical markers of T-cell activation (CD45RA/RO, HLA-DR, Ki67,
ICOS) or use of markers more specific to Treg subsets have been
considered. Such distinction among naïve and effector Treg sub-
sets allowed unveiling differences in HIV infection susceptibility
and homeostatic behavior during HIV infection. We and oth-
ers reported a preferential role for effector Treg compartment in
immune-regulation during HIV infection. This two-step discrim-
ination allows approaching Treg heterogeneity, but still remains
incomplete. High heterogeneity presumably stands among effector
cells and remains to be further investigated. A second classifica-
tion is based on the identification of natural versus peripherally
iTregs. Whereas understanding immune-regulation developing
during HIV infection may be greatly improved from the pre-
cocious analysis of iTregs, the current lack of a reliable marker
to identify these cells currently precludes consensual conclusions
to emerge. Despite major advances in recent years, this is the
early stage of Treg heterogeneity analysis in the context of HIV
infection. Further studies will hopefully identify deleterious and
beneficial Treg subsets and allow designing accurate restoration
strategies to reduce chronic immune inflammation during HIV
infection.
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